Recruitment Messages for Current Smokers Recently Diagnosed With Cancer
20 juli 2022 bijgewerkt door: University of Oklahoma
A Multimethod Evaluation of Tobacco Treatment Trial Recruitment Messages for Current Smokers Recently Diagnosed With Cancer: Pilot Factorial Randomized Controlled Trial
The objective of this study was to conduct a pilot factorial randomized trial to identify the message frames that are most effective in promoting participation in a tobacco treatment trial for current smokers recently diagnosed with cancer.
To do so, we used a multimethod approach to evaluate 3 different message frames across evaluation, effectiveness, and outcome measures.
We combine findings from a message design experiment with textual analytic software to provide a holistic understanding of how message frames may or may not differentially affect tobacco treatment trial participation within the context of a cancer diagnosis.
Studie Overzicht
Toestand
Voltooid
Conditie
Gedetailleerde beschrijving
Background: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.
Objective: This study aims to identify the message frames that were most effective in promoting intent to talk to a physician about participating in a tobacco treatment trial for smokers recently diagnosed with cancer.
Methods: From February to April 2019, current smokers diagnosed within the past 24 months were recruited from a national web-based panel for a multimethod pilot randomized trial (N=99). Participants were randomized to a 2×3 plus control factorial design that tested 3 unique message frames: proximal versus distal threats of smoking, costs of continued smoking versus benefits of quitting, and gains of participating versus losses of not participating in a tobacco treatment trial.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
99
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Jordan Neil
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Speak and understand English
- A recent cancer diagnosis (within the past 24 months)
- 18 years or older
- Report any cigarette use within the past 30 days
Exclusion Criteria:
- Do not speak or understand English
- Have not been diagnosed with cancer within the past 24 months
- Below the age of 18
- Does not report any cigarette use within the past 30 days
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Faculteitstoewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Sham-vergelijker: Control
The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
|
Does not include any of the three message factors.
|
|
Experimenteel: Proximal x Cost x Loss
Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
|
|
Experimenteel: Proximal x Cost x Gain
Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
|
|
Experimenteel: Proximal x Benefit x Gain
Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
|
|
Experimenteel: Proximal x Benefit x Loss
Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
|
|
Experimenteel: Distal x Cost x Gain
Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
|
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Experimenteel: Distal x Cost x Loss
Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
|
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Experimenteel: Distal x Benefit x Loss
Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
|
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Experimenteel: Distal x Benefit x Gain
Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
|
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Difference in intent to talk to a physician about participating in a smoking cessation study between factors.
Tijdsspanne: Within 30 minutes
|
The main effect within each message factor level was examined using ANOVA and compared with the control condition.
|
Within 30 minutes
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Predictors of intent to talk to a physician about participating in a smoking cessation study.
Tijdsspanne: Within 30 minutes
|
Other message evaluation and effectiveness measures were collected and explored in a multivariable model predicting intent to talk to a physician.
|
Within 30 minutes
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jordan Neil, Ph.D., TSET Health Promotion Research Center
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
11 februari 2019
Primaire voltooiing (Werkelijk)
1 april 2019
Studie voltooiing (Werkelijk)
2 april 2019
Studieregistratiedata
Eerst ingediend
13 juli 2022
Eerst ingediend dat voldeed aan de QC-criteria
20 juli 2022
Eerst geplaatst (Werkelijk)
22 juli 2022
Updates van studierecords
Laatste update geplaatst (Werkelijk)
22 juli 2022
Laatste update ingediend die voldeed aan QC-criteria
20 juli 2022
Laatst geverifieerd
1 juli 2022
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 2018P002035
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .